Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546492 · ClinicalTrials.gov registry record · Phase 4
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02546492 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 6 participants.
The verdict
NCT02546492, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open label safety and feasibility trial using Acthar® in addition to the investigators center-specific standard therapy, which could include increase in maintenance immunosuppression, high dose IVIG (intravenous immunoglobulin) (2 g/Kg), and/or Rituximab, in patients with chronic antibody-mediated rejection (CAMR).
Interventions
- DRUG Acthar gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546492
The ClinicalTrials.gov registry entry for NCT02546492 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acthar gel is the first listed.
NCT02546492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546492 about?
NCT02546492 is a clinical study titled "Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar". This is an open label safety and feasibility trial using Acthar® in addition to the investigators center-specific standard therapy, which could include increase in maintenance immunosuppression, high dose IVIG (intravenous immunoglobulin) (2 g/Kg), and/or Rituximab, in patients with chronic antibody...
What is the current status of trial NCT02546492?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2016-08. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT02546492?
The interventions under investigation include: Acthar gel (DRUG).
Who is sponsoring clinical trial NCT02546492?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.